- Home
- PHUN vs OTLK Comparison
PHUN vs OTLK Comparison
Compare PHUN & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- OTLK
- Stock Information
- Founded
- PHUN 2009
- OTLK 2010
- Country
- PHUN United States
- OTLK United States
- Employees
- PHUN N/A
- OTLK N/A
- Industry
- PHUN EDP Services
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PHUN Technology
- OTLK Health Care
- Exchange
- PHUN Nasdaq
- OTLK Nasdaq
- Market Cap
- PHUN 58.3M
- OTLK 48.3M
- IPO Year
- PHUN N/A
- OTLK 2016
- Fundamental
- Price
- PHUN $3.01
- OTLK $1.71
- Analyst Decision
- PHUN Buy
- OTLK Strong Buy
- Analyst Count
- PHUN 2
- OTLK 5
- Target Price
- PHUN $7.75
- OTLK $9.60
- AVG Volume (30 Days)
- PHUN 307.0K
- OTLK 823.9K
- Earning Date
- PHUN 08-07-2025
- OTLK 08-13-2025
- Dividend Yield
- PHUN N/A
- OTLK N/A
- EPS Growth
- PHUN N/A
- OTLK N/A
- EPS
- PHUN N/A
- OTLK 0.83
- Revenue
- PHUN $2,956,000.00
- OTLK N/A
- Revenue This Year
- PHUN $3.01
- OTLK N/A
- Revenue Next Year
- PHUN $50.72
- OTLK $379.84
- P/E Ratio
- PHUN N/A
- OTLK $2.06
- Revenue Growth
- PHUN N/A
- OTLK N/A
- 52 Week Low
- PHUN $2.22
- OTLK $0.87
- 52 Week High
- PHUN $14.60
- OTLK $9.25
- Technical
- Relative Strength Index (RSI)
- PHUN 46.91
- OTLK 46.49
- Support Level
- PHUN $3.07
- OTLK $1.65
- Resistance Level
- PHUN $3.30
- OTLK $1.97
- Average True Range (ATR)
- PHUN 0.23
- OTLK 0.12
- MACD
- PHUN -0.02
- OTLK -0.03
- Stochastic Oscillator
- PHUN 15.53
- OTLK 10.94
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.